Infection and Drug Resistance (Apr 2022)

Two Cases Report of Intrathecal Tigecycline Therapy for Intracranial Infection with Acinetobacter baumannii and Review of Literatures

  • Huang G,
  • Lai W,
  • Wu D,
  • Huang Q,
  • Zhong Q,
  • Ye X

Journal volume & issue
Vol. Volume 15
pp. 2211 – 2217

Abstract

Read online

Guanlin Huang, Wentao Lai, Daxing Wu, Qianliang Huang, Qi Zhong, Xinyun Ye Department of Neurosurgery, Ganzhou People’s Hospital, Ganzhou, Jiangxi, 341000, People’s Republic of ChinaCorrespondence: Xinyun Ye, Department of Neurosurgery, Ganzhou People’s Hospital, Ganzhou, Jiangxi, 341000, People’s Republic of China, Email [email protected]: Objective: To explore the treatment scheme for intracranial infection with Acinetobacter baumannii. Methods: We retrospective analyzed two cases of patients of intracranial infection with Acinetobacter baumannii. Results: The intracranial infection was controlled effectively by the scheme to intravenous“tigecycline + cefperazone-sulbactam”combined with intrathecal tigecycline injection, the two patients recover well with 21 months’ follow-up. Conclusions: Tigecycline-based drug scheme combined with intrathecal tigecycline injection can achieve the effect of controlling intracranial infection. Lumbar cisterna drainage tube plays a major role in controlling intracranial infection.Keywords: multidrug resistant Acinetobacter baumannii, intracranial infection, tigecycline

Keywords